Phase II Trial Of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer.

CONCLUSION: The study failed to meet the required 3 pCRs in the first 18 pts. The DFS in this population is encouraging and supports the hypothesis that select pts with rectal cancer may be spared from radiation.
PMID: 32649004 [PubMed - as supplied by publisher]

Source: The Oncologist - July 9, 2020 Category: Cancer & Oncology Authors: Barzi A, Choi A, Tsao-Wei D, Iqbal S, El-Khoueiry A, Agafitei DR, Cologne KG, Lenz HJ Tags: Oncologist Source Type: research